Alpha-adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS--implications for clinical practice (Q36371582)

13 August 2017

1 reference

title

Alpha-adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS--implications for clinical practice (English)

1 reference

13 August 2017

1 reference

Yassin A

1

1 reference

13 August 2017

Saad F

2

1 reference

13 August 2017

Hoesl CE

3

1 reference

13 August 2017

Traish AM

4

1 reference

13 August 2017

Hammadeh M

5

1 reference

13 August 2017

Shabsigh R

6

1 reference

13 August 2017

publication date

1 February 2006

1 reference

13 August 2017

1 reference

13 August 2017

volume

38

1 reference

13 August 2017

issue

1

1 reference

13 August 2017

page(s)

1-12

1 reference

Terazosin, doxazosin, and prazosin: current clinical experience

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

Natural history of benign prostatic hyperplasia and risk of prostatectomy. The Baltimore Longitudinal Study of Aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

The association between lower urinary tract symptoms and erectile dysfunction in four centres: the UrEpik study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

Medical therapy for benign prostatic hyperplasia: sexual dysfunction and impact on quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

Enhanced force generation by corpus cavernosum smooth muscle in rabbits with partial bladder outlet obstruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

The ups and downs of Rho-kinase and penile erection: upstream regulators and downstream substrates of rho-kinase and their potential role in the erectile response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

Excitatory alpha1-adrenergic receptors predominate over inhibitory beta-receptors in rabbit dorsal detrusor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

Observational multicentric trial performed with doxazosin: evaluation of sexual effects on patients with diagnosed benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

Combined oral therapy with sildenafil and doxazosin for the treatment of non-organic erectile dysfunction refractory to sildenafil monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

The clinical efficacy and tolerability of doxazosin standard and gastrointestinal therapeutic system for benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

Sexual dysfunction in men with lower urinary tract symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 alpha-reductase inhibitors GI198745 and finasteride

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

Extended-release alfuzosin hydrochloride: a new alpha-adrenergic receptor antagonist for symptomatic benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

Pharmacological evidence of distinct alpha 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

Erectile dysfunction (ED) is prevalent, bothersome and underdiagnosed in patients consulting urologists for benign prostatic syndrome (BPS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

The role of spinal and peripheral alpha1- and alpha2-adrenoceptors on bladder activity induced by bladder distension in anaesthetized rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

Sexual function in patients treated for benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

Efficacy of extended-release doxazosin and doxazosin standard in patients with concomitant benign prostatic hyperplasia and sexual dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

ISA, ISSAM and EAU recommendations for the investigation, treatment and monitoring of late-onset hypogonadism in males: scientific background and rationale

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

Noradrenaline contractions of human prostate mediated by alpha 1A-(alpha 1c-) adrenoceptor subtype

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

Effects of androgen manipulation on alpha1-adrenoceptor subtypes in the rat seminal vesicle.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

Worldwide experience with alfuzosin and tamsulosin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

Association between lower urinary tract symptoms and erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

Potential mechanisms of action of superselective alpha(1)-adrenoceptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

Altered in vitro adrenergic responses of dog detrusor muscle after chronic bladder outlet obstruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

Quality of life, mood, and sexual function: a path analytic model of treatment effects in men with erectile dysfunction and depressive symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

Impact of symptoms of prostatism on level of bother and quality of life of men in the French community.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

Sildenafil influences lower urinary tract symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

Male erectile dysfunction and health-related quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

Lower urinary tract symptoms/benign prostatic hyperplasia: minimizing morbidity caused by treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, open-label study. European Tamsulosin Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

Novel role for alpha1-adrenergic receptor subtypes in lower urinary tract symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

alpha1-adrenergic receptors in the lower urinary tract and vascular bed: potential role for the alpha1d subtype in filling symptoms and effects of ageing on vascular expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

Comparison of relaxation responses of cavernous and trigonal smooth muscles from rabbits by alpha1-adrenoceptor antagonists; prazosin, terazosin, doxazosin, and tamsulosin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

Therapy of ED: PDE-5 Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

Prejunctional facilitatory α1‐adrenoceptors in the rat urinary bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

Efficacy and tolerability of finasteride in symptomatic benign prostatic hyperplasia: a primary care study. Primary Care Investigator Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

A heterogeneous population of alpha 1 adrenergic receptors mediates contraction of human corpus cavernosum smooth muscle to norepinephrine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

Phentolamine mesylate relaxes penile corpus cavernosum tissue by adrenergic and non-adrenergic mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

Role of alpha adrenergic receptors in erectile function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

Effects of Medical or Surgical Castration on Erectile Function in an Animal Model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

Benign prostatic hyperplasia: age-related tissue-remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

Impact of erectile dysfunction on quality of life: patient and partner perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0272.2006.00709.X

10.1111/J.1439-0272.2006.00709.X

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference